Goldman Sachs Group Inc Zentalis Pharmaceuticals, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Zentalis Pharmaceuticals, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 634,064 shares of ZNTL stock, worth $1.85 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
634,064
Previous 619,253 2.39%
Holding current value
$1.85 Million
Previous $2.53 Million 8.1%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$2.9 - $4.57 $42,951 - $67,686
14,811 Added 2.39%
634,064 $2.33 Million
Q2 2024

Aug 13, 2024
BUY
$4.09 - $16.13 $1.17 Million - $4.63 Million
287,253 Added 86.52%
619,253 $2.53 Million
Q1 2024

May 15, 2024
BUY
$10.83 - $16.49 $423,658 - $645,072
39,119 Added 13.36%
332,000 $5.23 Million
Q4 2023

Feb 13, 2024
BUY
$9.84 - $20.13 $685,060 - $1.4 Million
69,620 Added 31.18%
292,881 $4.44 Million
Q3 2023

May 14, 2024
SELL
$19.63 - $28.29 $1.37 Million - $1.97 Million
-69,620 Reduced 23.77%
223,261 $4.48 Million
Q3 2023

Nov 14, 2023
SELL
$19.63 - $28.29 $10 Million - $14.4 Million
-510,316 Reduced 69.57%
223,261 $4.48 Million
Q2 2023

May 14, 2024
BUY
$17.41 - $30.05 $9.22 Million - $15.9 Million
529,631 Added 259.69%
733,577 $20.7 Million
Q2 2023

Aug 14, 2023
BUY
$17.41 - $30.05 $9.22 Million - $15.9 Million
529,631 Added 259.69%
733,577 $20.7 Million
Q1 2023

May 14, 2024
SELL
$16.14 - $24.94 $3.01 Million - $4.65 Million
-186,436 Reduced 47.76%
203,946 $3.51 Million
Q1 2023

May 11, 2023
SELL
$16.14 - $24.94 $3.01 Million - $4.65 Million
-186,436 Reduced 47.76%
203,946 $3.51 Million
Q4 2022

May 14, 2024
BUY
$18.07 - $25.6 $940,543 - $1.33 Million
52,050 Added 15.38%
390,382 $7.86 Million
Q4 2022

Feb 13, 2023
BUY
$18.07 - $25.6 $940,543 - $1.33 Million
52,050 Added 15.38%
390,382 $7.86 Million
Q3 2022

May 14, 2024
SELL
$20.23 - $31.73 $1.2 Million - $1.88 Million
-59,238 Reduced 14.9%
338,332 $7.33 Million
Q3 2022

Nov 10, 2022
SELL
$20.23 - $31.73 $1.2 Million - $1.88 Million
-59,238 Reduced 14.9%
338,332 $7.33 Million
Q2 2022

May 14, 2024
BUY
$17.91 - $52.25 $1.87 Million - $5.47 Million
104,689 Added 35.74%
397,570 $11.2 Million
Q2 2022

Aug 15, 2022
BUY
$17.91 - $52.25 $2.37 Million - $6.91 Million
132,324 Added 49.89%
397,570 $11.2 Million
Q1 2022

May 16, 2022
BUY
$41.58 - $80.89 $5.15 Million - $10 Million
123,877 Added 87.63%
265,246 $12.2 Million
Q4 2021

Feb 14, 2022
SELL
$66.92 - $84.79 $5.95 Million - $7.54 Million
-88,972 Reduced 38.63%
141,369 $11.9 Million
Q3 2021

Nov 10, 2021
BUY
$46.83 - $73.5 $10.8 Million - $16.9 Million
230,341 New
230,341 $15.4 Million

Others Institutions Holding ZNTL

# of Institutions
142
Shares Held
67.9M
Call Options Held
48.5K
Put Options Held
89.6K
View Full List

About Zentalis Pharmaceuticals, Inc.

ZNTL Quotes by TradingView
  • Ticker ZNTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,983,600
  • Market Cap $166M
  • Description
  • Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid ...
More about ZNTL
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email